GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Precision BioSciences DTIL · USD

Health Care · US listing · 🇺🇸 United States

Compare

9.68

-8.68%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

$68.7m

FY2016FY2024

Net income

$7.2m

FY2016FY2024

Free cash flow

−$58.7m

FY2016FY2024

Shareholders' equity

$56.4m

FY2016FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$68.7m$48.7m$25.1m$115.5m$24.3m$22.2m$10.9m$6.5m$7.0m
Gross profit$68.7m$48.7m$25.1m$115.5m$24.3m$22.2m$10.9m$6.5m$7.0m
Research and development$59.6m$53.4m$46.1m$115.2m$98.1m$82.4m$45.1m$20.3m$9.1m
Operating income−$26.2m−$43.7m−$62.3m−$39.4m−$109.8m−$87.2m−$47.9m−$22.0m−$8.8m
Net income$7.2m−$61.3m−$111.6m−$30.6m−$109.0m−$92.9m−$46.0m−$21.1m−$8.3m
Diluted earnings per share1.04-13.77-30.18-15.07-62.29-54.63-41.04-21.10-0.32

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$136.4m$159.8m$238.2m$211.5m$150.2m$235.2m$138.6m$72.7m$98.4m
Cash and short-term investments$86.3m$116.7m$189.6m$143.7m$89.8m$180.9m$103.2m$62.8m$93.4m
Total liabilities$80.0m$140.9m$177.7m$120.3m$105.7m$96.9m$98.6m$99.1m$103.2m
Debt$30.0m$31.3m$25.0m$9.1m$10.5m$6.8m$3.3m$1.5m—
Shareholders' equity$56.4m$18.9m$60.4m$91.2m$44.4m$138.3m$40.0m−$26.4m−$4.7m
Shares outstanding7m4m4m2m2m2m1m1m26m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$58.4m−$84.1m−$45.8m−$10.9m−$87.4m−$73.6m−$51.7m−$24.2m$92.3m
Capital spending−$250,000−$2.3m−$3.3m−$5.8m−$5.0m−$24.7m−$15.7m−$5.6m−$2.1m
Free cash flow−$58.7m−$86.4m−$49.1m−$16.7m−$92.4m−$98.3m−$67.4m−$29.7m$90.2m
Dividends paid————————−$12.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue—$10.8m$34.2m$13,000$18,000$29,000$638,000$576,000
Gross profit—$10.8m$34.2m$13,000$18,000$29,000$638,000$576,000
Operating income−$19.2m−$9.1m$12.5m−$20.7m−$21.9m−$22.1m−$24.8m−$21.3m
Net income−$32.7m−$18.4m$20.1m−$21.8m−$23.5m−$20.6m−$17.7m−$16.4m
Diluted earnings per share-1.26-0.711.05-1.14-1.23-1.07-2.58-2.39
Cash from operations−$13.0m−$11.0m−$11.0m−$15.0m−$20.0m−$19.0m−$18.0m−$5.0m
Total assets$125.9m$143.9m$154.4m$93.5m$108.9m$124.4m$136.4m$153.3m
Cash and short-term investments$87.5m$101.2m$115.6m$44.9m$62.2m$77.2m$86.3m$101.2m
Debt$24.0m$1.6m$23.9m$23.8m$23.8m$23.7m$23.6m$23.6m
Shareholders' equity$45.3m$76.1m$92.2m$16.6m$34.1m$49.3m$56.4m$64.9m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue10.9%7.1%—
Operating income-5.8%-13.8%—
Net income-25.7%-15.9%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin100.0%100.0%100.0%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings-1.73.7-0.8-1.2-14.7-4.0-7.6
Price to sales2.30.41.05.33.918.031.9

Share price return

Finished calendar years

2025202420232022202120202019
Return9%-62%-69%-86%-9%-37%70%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 30-to-1 reverse split · 14 Feb 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.